(R)-Roscovitine (CYC202, Seliciclib) sensitizes SH-SY5Y neuroblastoma cells to nutlin-3-induced apoptosis

Experimental Cell Research

Volumn 312, Issue 12, 2006, Pages 2394-2400

  Ribas, Judit ^a,b   Boix, Jacint ^b   Meijer, Laurent ^a  

^a CNRS   (France)

^b Universitat de Lleida Facultat de Medicina Sabadell   (Spain)

Author keywords

(R) Roscovitine; Apoptosis; Cancer; CYC202; Cyclin; Cyclin dependent kinase; HDM2; Nutlin 3; p53; Seliciclib

Indexed keywords

IMIDAZOLINE DERIVATIVE; NUTLIN 3; PROTEIN BCL XL; PROTEIN P53; ROSCOVITINE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; SENSITIZATION; WESTERN BLOTTING;

EID: 33745488640     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2006.04.021     Document Type: Article

References (24)

1. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., Lukacs C., Klein C., Fotouhi N., and Liu E.A. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303 (2004) 844-848
2. Oliner J.D., Kinzler K.W., Meltzer P.S., George D.L., and Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358 (1992) 80-83
3. Wu X., Bayle J.H., Olson D., and Levine A.J. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7 (1993) 1126-1132
4. Fischer P.M., and Gianella-Borradori A. Recent progress in the discovery and development of cyclin-dependent kinase inhibitors. Expert Opin. Investig. Drugs 14 (2005) 457-477
5. Benson C., Kaye S., Workman P., Garrett M., Walton M., and de Bono J. Clinical anticancer drug development: targeting the cyclin-dependent kinases. Br. J. Cancer 92 (2005) 7-12
6. Meijer L., and Raymond E. Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Accounts Chem. Res. 36 (2003) 417-425
7. Guzi T. Cyc-202 cyclacel. Curr. Opin. Investig. Drugs 5 (2004) 1311
8. L. Meijer, K. Bettayeb, H. Galons, Roscovitine (CYC202, Seliciclib). In CDK inhibitors and their potential as anti-tumor agents, E. Yue, P.J. Smith (eds), CRC Press: Boca Raton, (in press).
9. Mgbonyebi O.P., Russo J., and Russo I.H. Roscovitine induces cell death and morphological changes indicative of apoptosis in MDA-MB-231 breast cancer cells. Cancer Res. 59 (1999) 1903-1910
10. Hahntow I.N., Schneller F., Oelsner M., Weick K., Ringshausen I., Fend F., Peschel C., and Decker T. Cyclin-dependent kinase inhibitor roscovitine induces apoptosis in chronic lymphocytic leukemia cells. Leukemia 18 (2004) 747-755
11. Ribas J., and Boix J. Cell differentiation, caspase inhibition and macromolecular synthesis blockage, but not Bcl-2 or Bcl-XL proteins, protect SH-SY5Y cells from apoptosis triggered by two CDK inhibitory drugs. Exp. Cell Res. 295 (2004) 9-24
12. Maggiorella L., Deutsch E., Frascogna V., Chavaudra N., Jeanson L., Milliat F., Eschwege F., and Bourhis J. Enhancement of radiation response by roscovitine in human breast carcinoma in vitro and in vivo. Cancer Res. 63 (2003) 2513-2517
13. Edamatsu H., Gau C.L., Nemoto T., Guo L., and Tamanoi F. Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines. Oncogene 19 (2000) 3059-3068
14. Senderowicz A.M. Novel small molecule cyclin-dependent kinases modulators in human clinical trials. Cancer Biol. Ther. 2 (2003) S84-S95
15. Cui H., Schroering A., and Ding H.F. p53 mediates DNA damaging drug-induced apoptosis through a caspase-9-dependent pathway in SH-SY5Y neuroblastoma cells. Mol. Cancer Ther. 1 (2002) 679-686
16. Yuste V.J., Sanchez-Lopez I., Sole C., Encinas M., Bayascas J.R., Boix J., and Comella J.X. The prevention of the staurosporine-induced apoptosis by Bcl-X(L), but not by Bcl-2 or caspase inhibitors, allows the extensive differentiation of human neuroblastoma cells. J. Neurochem. 80 (2002) 126-139
17. Erster S., and Moll U.M. Stress-induced p53 runs a transcription-independent death program. Biochem. Biophys. Res. Commun. 331 (2005) 843-850
18. Yu J., and Zhang L. The transcriptional targets of p53 in apoptosis control. Biochem. Biophys. Res. Commun. 331 (2005) 851-858
19. Meijer L., Borgne A., Mulner O., Chong J.P.J., Blow J.J., Inagaki N., Inagaki M., Delcros J.G., and Moulinoux J.P. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. 243 (1997) 527-536
20. Fabian M.A., Biggs III W.H., Treiber D.K., Atteridge C.E., Azimioara M.D., Benedetti M.G., Carter T.A., Ciceri P., Edeen P.T., Floyd M., Ford J.M., Galvin M., Gerlach J.L., Grotzfeld R.M., Herrgard S., Insko D.E., Insko M.A., Lai A.G., Lelias J.M., Mehta S.A., Milanov Z.V., Velasco A.M., Wodicka L.M., Patel H.K., Zarrinkar P.P., and Lockhart D.J. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23 (2005) 329-336
21. Bach S., Knockaert M., Reinhardt J., Lozach O., Schmitt S., Baratte B., Koken M., Coburn S.P., Tang L., Jiang T., Liang D.C., Galons H., Dierick J.F., Pinna L.A., Meggio F., Totzke F., Schachtele C., Lerman A.S., Carnero A., Wan Y., Gray N., and Meijer L. Roscovitine targets: protein kinases and pyridoxal kinase. J. Biol. Chem. 280 (2005) 31208-31219
22. Lu W., Chen L., Peng Y., and Chen J. Activation of p53 by roscovitine-mediated suppression of MDM2 expression. Oncogene 20 (2001) 3206-3216
23. O'Hagan H.M., and Ljungman M. Nuclear accumulation of p53 following inhibition of transcription is not due to diminished levels of MDM2. Oncogene 23 (2004) 5505-5512
24. Zhu Y., Alvarez C., Doll R., Kurata H., Schebye X.M., Parry D., and Lees E. Intra-S-phase checkpoint activation by direct CDK2 inhibition. Mol. Cell. Biol. 24 (2004) 6268-6277